Dr. Mark E. Kutner, MD

Medicare patients and services

Medicare patients, 2024

149

Services billed

1,050

Patients’ average age

76

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 30 companies reported 138 payments worth $3,889 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 26 industry-funded studies in 2025, from 14 companies. The companies reported $3,549,748 in research payments for these studies, mostly to the institutions running them.

• A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
  Eli Lilly and Company · Active, not recruiting · NCT06662383
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
  Eli Lilly and Company · Completed · NCT05929066
• A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
  ModernaTX, Inc. · Completed · NCT06508320
• A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
  Eli Lilly and Company · Active, not recruiting · NCT06292013
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
  Eli Lilly and Company · Active, not recruiting · NCT06383390
• A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
  Eli Lilly and Company · Completed · NCT06074562
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
  Eli Lilly and Company · Active, not recruiting · NCT07035093
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
  ModernaTX, Inc. · Completed · NCT05330975
• A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
  Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Internal Medicine clinicians in Miami

• Tony Abbassi, MD
• Haleem S. Abdul, M.D.
• Simon C. Abelson, MD
• Nicolas Acquavella Pesantes, M.D
• Mavara M. Agrawal, MD
• Richard B. Aguilar, M.D.
• Dania M. Aguirre, M.D.
• Madiha Ahmed, MD